• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

常规筛查接受性别肯定激素治疗的跨性别和性别多样化成年人:一项叙述性综述。

Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.

机构信息

Division of Endocrinology, Metabolism & Diabetes, Department of Medicine, University of Colorado, Anschutz Medical Campus, 12801 E 17th Ave, Aurora, CO, 80045, USA.

Department of Endocrinology, Medicine Service, Rocky Mountain Regional Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, Aurora, 80045, CO, USA.

出版信息

J Gen Intern Med. 2021 May;36(5):1380-1389. doi: 10.1007/s11606-021-06634-7. Epub 2021 Feb 5.

DOI:10.1007/s11606-021-06634-7
PMID:33547576
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8131455/
Abstract

Despite the growing number of adult transgender and gender diverse (TGD) patients seeking health services, there are many unknowns regarding how routine screening recommendations should be applied to TGD persons receiving gender-affirming hormone therapy (GAHT). Patients taking GAHT may have disease risks that differ from what is expected based on their sex assigned at birth or affirmed gender identity. We discuss two patient cases, one transgender man and one transgender woman who present for routine medical care, to review several conditions that may be impacted by the hormones utilized in masculinizing and feminizing GAHT and for which screening recommendations are available for TGD adults: cardiovascular risk factors, osteoporosis, breast cancer, cervical cancer, and prostate cancer. We reviewed the TGD-specific screening recommendations from several major medical organizations and programs and found them to be largely based upon expert opinion due to a lack of evidence. The goal of this narrative review is to assist healthcare professionals in counseling and screening their TGD patients when and where appropriate. Not all TGD adults have the ability or need to receive routine medical care from a specialized TGD health clinic; therefore, it is essential for all healthcare professionals involved in routine and gender-affirming care to have knowledge about these conditions and screenings.

摘要

尽管越来越多的成年跨性别和性别多样化(TGD)患者寻求医疗服务,但对于如何将常规筛查建议应用于接受性别肯定激素治疗(GAHT)的 TGD 患者,仍有许多未知之处。接受 GAHT 的患者可能存在与基于出生时分配的性别或确认的性别认同所预期的不同的疾病风险。我们讨论了两个患者病例,一个是跨性别男性,一个是跨性别女性,他们因常规医疗护理就诊,以回顾几种可能受到用于男性化和女性化 GAHT 的激素影响的疾病,以及针对 TGD 成年人的可用筛查建议:心血管危险因素、骨质疏松症、乳腺癌、宫颈癌和前列腺癌。我们回顾了几个主要医疗组织和项目的 TGD 特定筛查建议,发现它们主要基于专家意见,因为缺乏证据。本叙述性综述的目的是帮助医疗保健专业人员在适当的时候为 TGD 患者提供咨询和筛查。并非所有 TGD 成年人都有能力或需要从专门的 TGD 健康诊所获得常规医疗护理;因此,所有参与常规和性别肯定护理的医疗保健专业人员都必须了解这些疾病和筛查。

相似文献

1
Routine Screening for Transgender and Gender Diverse Adults Taking Gender-Affirming Hormone Therapy: a Narrative Review.常规筛查接受性别肯定激素治疗的跨性别和性别多样化成年人:一项叙述性综述。
J Gen Intern Med. 2021 May;36(5):1380-1389. doi: 10.1007/s11606-021-06634-7. Epub 2021 Feb 5.
2
Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks.跨性别和性别多样化人群的性别肯定激素治疗:治疗方式、监测和风险概述。
Neurourol Urodyn. 2023 Jun;42(5):903-920. doi: 10.1002/nau.25097. Epub 2022 Nov 20.
3
Clinicians in the Veterans Health Administration initiate gender-affirming hormone therapy in concordance with clinical guideline recommendations.退伍军人健康管理局的临床医生根据临床指南建议启动性别肯定激素治疗。
Front Endocrinol (Lausanne). 2024 May 10;15:1086158. doi: 10.3389/fendo.2024.1086158. eCollection 2024.
4
Barriers and Facilitators to Gender-affirming Hormone Therapy in the Veterans Health Administration.退伍军人事务部中性别肯定激素治疗的障碍和促进因素。
Ann Behav Med. 2023 Nov 16;57(12):1014-1023. doi: 10.1093/abm/kaad035.
5
Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy.出生时被指定为女性的跨性别者的骨骼健康:性别肯定激素治疗和性腺切除术的影响。
Front Endocrinol (Lausanne). 2024 Sep 26;15:1416121. doi: 10.3389/fendo.2024.1416121. eCollection 2024.
6
Characteristics of a transgender and gender-diverse patient population in Utah: Use of electronic health records to advance clinical and health equity research.犹他州跨性别和性别多样化患者人群的特征:利用电子健康记录推进临床和健康公平研究。
PLoS One. 2024 May 7;19(5):e0302895. doi: 10.1371/journal.pone.0302895. eCollection 2024.
7
Breast care considerations for transgender and gender-diverse patients.跨性别和性别多样化患者的乳房保健注意事项。
Womens Health (Lond). 2024 Jan-Dec;20:17455057241289706. doi: 10.1177/17455057241289706.
8
Laboratory Changes During Gender-Affirming Hormone Therapy in Transgender Adolescents. transgender 青少年进行性别肯定激素治疗期间的实验室变化。
Pediatrics. 2024 May 1;153(5). doi: 10.1542/peds.2023-064380.
9
Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study.雄激素性脱发在跨性别和性别多样化人群中的发病率:一项回顾性对比队列研究。
J Am Acad Dermatol. 2023 Sep;89(3):504-510. doi: 10.1016/j.jaad.2023.01.037. Epub 2023 Feb 11.
10
Reproductive health risks and clinician practices with gender diverse adolescents and young adults.生殖健康风险和跨性别青少年及年轻成人的临床医生实践。
Andrology. 2021 Nov;9(6):1689-1697. doi: 10.1111/andr.13026. Epub 2021 May 24.

引用本文的文献

1
Underinvested, Under-Referred, and Underserved: Applying a Gender Equity Continuum Framework in Cancer Control Continuum Programs and Policies to Expand to Transgender and Nonbinary Populations.投资不足、转诊不足和服务不足:在癌症控制连续项目和政策中应用性别平等连续统一体框架,以扩大至跨性别和非二元性别群体。
JCO Oncol Adv. 2025 May 7;2(1):e2400023. doi: 10.1200/OA.24.00023. eCollection 2025.
2
Oncological needs in transgender patients.transgender患者的肿瘤学需求。
Clin Transl Oncol. 2025 Apr 18. doi: 10.1007/s12094-025-03917-x.
3
Immune dynamics throughout life in relation to sex hormones and perspectives gained from gender-affirming hormone therapy.一生中与性激素相关的免疫动力学以及从性别确认激素治疗中获得的见解。
Front Immunol. 2025 Jan 16;15:1501364. doi: 10.3389/fimmu.2024.1501364. eCollection 2024.
4
Hormone therapy and cancer risks in transgender people: a systematic review.transgender人群中的激素治疗与癌症风险:一项系统综述
Epidemiol Serv Saude. 2025 Jan 10;33(spe1):e2024319. doi: 10.1590/S2237-96222024v33e2024319.especial.en. eCollection 2025.
5
UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risks.英国对患有遗传性癌症风险的跨性别和性别多样化患者的管理建议。
BJC Rep. 2023 Jun 22;1(1):1. doi: 10.1038/s44276-023-00002-0.
6
Cardiovascular disease risk in the transgender population.跨性别者群体的心血管疾病风险。
Arch Cardiol Mex. 2023;93(Supl):26-30. doi: 10.24875/ACM.M23000091.
7
Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022.30个关于肥胖的误区、误解和/或过度简化观点:肥胖医学协会(OMA)2022年临床实践声明(CPS)
Obes Pillars. 2022 Aug 10;3:100034. doi: 10.1016/j.obpill.2022.100034. eCollection 2022 Sep.
8
Gender-affirming hormone therapy, mental health, and surgical considerations for aging transgender and gender diverse adults.老年跨性别和性别多样化成年人的性别肯定激素治疗、心理健康及手术考量
Ther Adv Endocrinol Metab. 2023 Apr 19;14:20420188231166494. doi: 10.1177/20420188231166494. eCollection 2023.
9
Determining the Sex Assigned at Birth of Transgender and Nonbinary Populations in Administrative Claims Databases Utilizing Diagnostic and Procedure Codes.利用诊断和程序代码在行政索赔数据库中确定跨性别和非二元性别群体的出生时指定性别。
Transgend Health. 2023 Mar 31;8(2):130-136. doi: 10.1089/trgh.2021.0127. eCollection 2023 Apr.
10
Effects of Hormones on Breast Development and Breast Cancer Risk in Transgender Women.激素对跨性别女性乳房发育及乳腺癌风险的影响。
Cancers (Basel). 2022 Dec 30;15(1):245. doi: 10.3390/cancers15010245.

本文引用的文献

1
Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation.2012 年美国预防服务工作组建议发布后,PSA 检测和前列腺癌发病率的种族和民族差异。
J Natl Cancer Inst. 2021 Jun 1;113(6):719-726. doi: 10.1093/jnci/djaa171.
2
Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.绝经激素治疗与妇女健康倡议随机临床试验长期随访中乳腺癌发病率和死亡率的关系。
JAMA. 2020 Jul 28;324(4):369-380. doi: 10.1001/jama.2020.9482.
3
Healthcare Policy Changes in Osteoporosis Can Improve Outcomes and Reduce Costs in the United States.美国骨质疏松症医疗保健政策的变化可改善治疗效果并降低成本。
JBMR Plus. 2019 May 13;3(9):e10192. doi: 10.1002/jbm4.10192. eCollection 2019 Sep.
4
Assessing gender identity differences in cardiovascular disease in US adults: an analysis of data from the 2014-2017 BRFSS.评估美国成年人心血管疾病中的性别认同差异:来自 2014-2017 年 BRFSS 的数据分析。
J Behav Med. 2020 Apr;43(2):329-338. doi: 10.1007/s10865-019-00102-8. Epub 2019 Sep 26.
5
Fracture Risk in Trans Women and Trans Men Using Long-Term Gender-Affirming Hormonal Treatment: A Nationwide Cohort Study.使用长期性别确认激素治疗的跨性别女性和跨性别男性的骨折风险:一项全国性队列研究。
J Bone Miner Res. 2020 Jan;35(1):64-70. doi: 10.1002/jbmr.3862. Epub 2019 Oct 7.
6
Bone Health in the Transgender Population.跨性别群体的骨骼健康
Clin Rev Bone Miner Metab. 2019 Jun;17(2):77-85. doi: 10.1007/s12018-019-09261-3. Epub 2019 Jul 2.
7
Bone Densitometry in Transgender and Gender Non-Conforming (TGNC) Individuals: 2019 ISCD Official Position.跨性别和性别不符合(TGNC)个体的骨密度测定:2019ISCD 官方立场。
J Clin Densitom. 2019 Oct-Dec;22(4):544-553. doi: 10.1016/j.jocd.2019.07.004. Epub 2019 Jul 10.
8
Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands.接受激素治疗的跨性别者的乳腺癌风险:荷兰全国队列研究。
BMJ. 2019 May 14;365:l1652. doi: 10.1136/bmj.l1652.
9
Cardiovascular Disease Risk Factors and Myocardial Infarction in the Transgender Population.跨性别群体中的心血管疾病风险因素与心肌梗死
Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005597. doi: 10.1161/CIRCOUTCOMES.119.005597.
10
Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy.接受激素治疗的 transgender 个体中急性心血管事件的发生情况 。 注:“transgender”在医学领域较生僻,可根据具体语境进一步准确理解其含义,比如可能是“跨性别者”等意思。
Circulation. 2019 Mar 12;139(11):1461-1462. doi: 10.1161/CIRCULATIONAHA.118.038584.